Tofacitinib Ointment For Chronic Plaque Psoriasis
- Conditions
- Psoriasis VulgarisPsoriasis
- Interventions
- Drug: placebo ointment (vehicle)
- Registration Number
- NCT01831466
- Lead Sponsor
- Pfizer
- Brief Summary
The study is beng done to test if tofacitinib ointment is safe and effective for people with plaque psoriasis. Two dose strengths of tofacitinib ointment (20 mg/g and 10 mg/g) applied once or twice daily are being tested. The safety and effectiveness of tofacitinib ointment used for 12 weeks will be compared to the safety and effectiveness of placebo ointment (vehicle) used for 12 weeks.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 476
- Have mild, moderate or severe plaque psoriasis (psoriasis vulgaris) for at least 6 months prior to Baseline
- At Baseline, have plaque psoriasis covering 2% to 20% of total body surface area (BSA) on the trunk and limbs (excluding palms, soles, and nails)
- If received certain treatments, should be off treatment for a minimum period of time (washout)
- Currently have non-plaque forms of psoriasis or drug-induced psoriasis
- Require treatment with or cannot stop medication(s) prohibited during the study
- Have certain laboratory abnormalities at Baseline
- Current or history of certain infections
- Females who are pregnant, breastfeeding, or are of childbearing potential not using highly effective contraception
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Treatment Group C placebo ointment (vehicle) - Treatment Group E tofacitinib ointment 10 mg/g - Treatment Group F placebo ointment (vehicle) - Treatment Group A tofacitinib ointment 20 mg/g - Treatment Group B tofacitinib ointment 10 mg/g - Treatment Group D tofacitinib ointment 20 mg/g -
- Primary Outcome Measures
Name Time Method Percentage of Participants Achieving a PGA-C Response of Clear (0) or Almost Clear (1) and Greater Than or Equal to (≥) 2 Grade/Point Improvement From Baseline at Week 12 Baseline, Week 12 Clinical signs of plaque psoriasis (erythema \[E\], induration \[I\], and scaling \[S\]) were scored separately according to a 5-point severity scale (0 to 4) to provide PGA subscores, which described the overall severity of each clinical sign. The PGA-C was a static assessment; i.e., without regard to a previous assessment. The PGA subscores are then summed and averaged after which the total average was rounded to the nearest whole number to determine the PGA-C score and category. A higher score indicated a higher level of severity. 0 is equal to (=) cleared except for any residual discoloration and 1=almost clear, majority of lesions had individual scores for E+I+S that when summed, averaged, and rounded equaled 1.
Percentage of Participants Achieving a PGA-C Response of Clear (0) or Almost Clear (1) and ≥2 Grade/Point Improvement From Baseline at Week 8 Baseline, Week 8 Clinical signs of plaque psoriasis (E, I, and S) were scored separately according to a 5-point severity scale (0 to 4) to provide PGA subscores, which described the overall severity of each clinical sign. The PGA-C was a static assessment; i.e., without regard to a previous assessment. The PGA subscores are then summed and averaged after which the total average was rounded to the nearest whole number to determine the PGA-C score and category. A higher score indicated a higher level of severity. 0 is equal to (=) cleared except for any residual discoloration and 1=almost clear, majority of lesions had individual scores for E+I+S that when summed, averaged, and rounded equaled 1.
- Secondary Outcome Measures
Name Time Method Percentage of Participants Achieving a PGA-G Response of Clear (0) or Almost Clear (1) and ≥2 Grade/Point Improvement From Baseline at Week 8 Baseline, Week 8 Clinical signs of plaque psoriasis (E, I and S) were scored separately according to a 5-point severity scale (0 to 4) to provide PGA subscores, which described the overall severity of each clinical sign. After scoring each of the PGA subscores, a clinical evaluator of psoriasis performed an assessment of the overall severity of psoriasis and assigned a PGA-G score and category. 0=Clear, except for any residual discoloration (post-inflammatory hyperpigmentation and/or hypopigmentation) and 1=almost clear, the psoriasis is not entirely cleared and remaining plaques are light pink (not including post inflammatory hyperpigmentation), and/or have barely palpable elevation and/or have occasional fine scale. The PGA-G was a static assessment; i.e., without regard to a previous assessment.
Change From Baseline to Week 8 in Clinic-Based ISI Scores Baseline, Week 8 The severity of itch (pruritus) due to psoriasis was assessed using the ISI. Participants were asked to assess their "worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "no itching" (0) and "worst possible itching" (10) at the ends. Participants completed the ISI assessments at the clinic (i.e., clinic-based).
Change From Baseline to Week 12 in the Dermatology Life Quality Index (DLQI) Total Score Baseline, Week 12 DLQI is the dermatology-specific quality of life measure used for psoriatic population. The 10-item questionnaire assesses participant health-related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.
Percent Change From Baseline to Week 8 in PASI Baseline, Week 8 Combined assessment of lesion severity and area affected into single score. Body was divided into 4 regions: head, arms, trunk, legs. For each region, percent area of skin involved was estimated: 0=0% to 6=90-100%. Severity was estimated by clinical signs: erythema, induration, scaling; scale: 0=none to 4=maximum. Final PASI = sum of severity parameters for each region\*area score\*weight of region (head: 0.1, arms: 0.2, body: 0.3, legs: 0.4); total possible score range: 0=no disease to 72=maximal disease. The maximum PASI score was \<72 since the PASI assessment excluded scalp, palms, finger nails, soles, and toe nails.
Percentage of Participants Achieving a PGA-C Response of Clear (0) or Almost Clear (1) at Week 12 Week 12 Clinical signs of plaque psoriasis (E, I, and S) were scored separately according to a 5-point severity scale (0 to 4) to provide PGA subscores, which described the overall severity of each clinical sign. The PGA-C was a static assessment; i.e., without regard to a previous assessment. The PGA subscores are then summed and averaged after which the total average was rounded to the nearest whole number to determine the PGA-C score and category. A higher score indicated a higher level of severity. 0 is equal to (=) cleared except for any residual discoloration and 1=almost clear, majority of lesions had individual scores for E+I+S that when summed, averaged, and rounded equaled 1.
Percentage of Participants Achieving a Gestalt Physician's Global Assessment (PGA-G) Response of Clear (0) or Almost Clear (1) and ≥2 Grade/Point Improvement From Baseline at Week 12 Baseline, Week 12 Clinical signs of plaque psoriasis (E, I and S) were scored separately according to a 5-point severity scale (0 to 4) to provide PGA subscores, which described the overall severity of each clinical sign. After scoring each of the PGA subscores, a clinical evaluator of psoriasis performed an assessment of the overall severity of psoriasis and assigned a PGA-G score and category. 0=Clear, except for any residual discoloration (post-inflammatory hyperpigmentation and/or hypopigmentation) and 1=almost clear, the psoriasis is not entirely cleared and remaining plaques are light pink (not including post inflammatory hyperpigmentation), and/or have barely palpable elevation and/or have occasional fine scale. The PGA-G was a static assessment; i.e., without regard to a previous assessment.
Percentage of Participants Achieving a PGA-C Response of Clear (0) or Almost Clear (1) at Week 8 Week 8 Clinical signs of plaque psoriasis (E, I, and S) were scored separately according to a 5-point severity scale (0 to 4) to provide PGA subscores, which described the overall severity of each clinical sign. The PGA-C was a static assessment; i.e., without regard to a previous assessment. The PGA subscores are then summed and averaged after which the total average was rounded to the nearest whole number to determine the PGA-C score and category. A higher score indicated a higher level of severity. 0 is equal to (=) cleared except for any residual discoloration and 1=almost clear, majority of lesions had individual scores for E+I+S that when summed, averaged, and rounded equaled 1.
Percent Change From Baseline to Week 12 in Psoriasis Area and Severity Index (PASI) Baseline, Week 12 Combined assessment of lesion severity and area affected into single score. Body was divided into 4 regions: head, arms, trunk, legs. For each region, percent (%) area of skin involved was estimated: 0=0% to 6=90-100%. Severity was estimated by clinical signs: erythema, induration, scaling; scale: 0=none to 4=maximum. Final PASI = sum of severity parameters for each region\*area score\*weight of region (head: 0.1, arms: 0.2, body: 0.3, legs: 0.4); total possible score range: 0=no disease to 72=maximal disease. The maximum PASI score was \<72 since the PASI assessment excluded scalp, palms, finger nails, soles, and toe nails.
Percent Change From Baseline to Week 12 in Body Surface Area (BSA) Affected With Psoriasis Baseline, Week 12 Assessment of BSA with psoriasis was performed separately for 4 body regions: head and neck, upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). The percent surface area with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant represents approximately 1% of the total BSA. The number of handprints of psoriatic skin in a body region can be used to determine the extent (%) to which a body regions is involved with psoriasis. BSA (%)=the sum of the BSAs of the 4 body regions. BSA assessment excluded head and neck, palms, finger nails, soles and toe nails.
Percent Change From Baseline to Week 8 in BSA Affected With Psoriasis Baseline, Week 8 Assessment of BSA with psoriasis was performed separately for 4 body regions: head and neck, upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). The percent surface area with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant represents approximately 1% of the total BSA. The number of handprints of psoriatic skin in a body region can be used to determine the extent (%) to which a body regions is involved with psoriasis. BSA (%)=the sum of the BSAs of the 4 body regions. BSA assessment excluded head and neck, palms, finger nails, soles and toe nails.
Change From Baseline to Week 12 in Clinic-Based Itch Severity Item (ISI) Scores Baseline, Week 12 The severity of itch (pruritus) due to psoriasis was assessed using the ISI. Participants were asked to assess their "worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "no itching" (0) and "worst possible itching" (10) at the ends. Participants completed the ISI assessments at the clinic (i.e., clinic-based).
Percentage of Participants Achieving at Least a 75% Reduction in PASI Response (PASI75), Relative to Baseline at Week 12 Baseline, Week 12 Combined assessment of lesion severity and area affected into single score. Body was divided into 4 regions: head, arms, trunk, legs. For each region, percent area of skin involved was estimated: 0=0% to 6=90-100%. Severity was estimated by clinical signs: erythema, induration, scaling; scale: 0=none to 4=maximum. Final PASI = sum of severity parameters for each region\*area score\*weight of region (head: 0.1, arms: 0.2, body: 0.3, legs: 0.4); total possible score range: 0=no disease to 72=maximal disease. The maximum PASI score was \<72 since the PASI assessment excluded scalp, palms, finger nails, soles, and toe nails.
Percentage of Participants Achieving a Patient's Global Assessment (PtGA) Response of Clear (0) or Almost Clear (1) and ≥2 Grade/Point Improvement From Baseline at Week 12 for Participants With a PtGA Score ≥2 at Baseline Baseline, Week 12 The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5-point scale (0=clear; 1=almost clear; 2=mild; 3=moderate; 4=severe).
Percentage of Participants Achieving a PtGA Response of Clear (0) or Almost Clear (1) and ≥2 Grade/Point Improvement From Baseline at Week 8 for Participants With a PtGA Score ≥2 at Baseline Baseline, Week 8 The PtGA asks the participant to evaluate the overall cutaneous disease at that point in time on a single item, 5-point scale (0=clear; 1=almost clear; 2=mild; 3=moderate; 4=severe).
Percentage of Participants Achieving PASI75, Relative to Baseline at Week 8 Baseline, Week 8 Combined assessment of lesion severity and area affected into single score. Body was divided into 4 regions: head, arms, trunk, legs. For each region, percent area of skin involved was estimated: 0=0% to 6=90-100%. Severity was estimated by clinical signs: erythema, induration, scaling; scale: 0=none to 4=maximum. Final PASI = sum of severity parameters for each region\*area score\*weight of region (head: 0.1, arms: 0.2, body: 0.3, legs: 0.4); total possible score range: 0=no disease to 72=maximal disease. The maximum PASI score was \<72 since the PASI assessment excluded scalp, palms, finger nails, soles, and toe nails.
Change From Baseline to Week 8 in the DLQI Total Score Baseline, Week 8 DLQI is the dermatology-specific quality of life measure used for psoriatic population. The 10-item questionnaire assesses participant health-related quality of life (daily activities, personal relationships, symptoms and feelings, leisure, work and school, and treatment). The DLQI questions are rated by the participant as 0 (not at all/not relevant) to 3 (very much) with a total score range of 0 (best) to 30 (worst); higher scores indicate poor quality of life.
Trial Locations
- Locations (52)
MedaPhase Inc.
🇺🇸Newnan, Georgia, United States
NZOZ Solumed
🇵🇱Poznan, Wielkopolskie, Poland
Dermadvances Research
🇨🇦Winnipeg, Manitoba, Canada
Health Concepts
🇺🇸Rapid City, South Dakota, United States
Pomorskie Centrum Traumatologii im.Mikolaja Kopernika w Gdansku Oddzial Dermatologii
🇵🇱Gdansk, Poland
Stratica Medical
🇨🇦Edmonton, Alberta, Canada
The Guenther Dermatology Research Centre
🇨🇦London, Ontario, Canada
CCA Medical Research Corporation
🇨🇦Ajax, Ontario, Canada
Dermatrials Research
🇨🇦Hamilton, Ontario, Canada
Radiant Research, Inc.
🇺🇸Greer, South Carolina, United States
Siena Medical Research
🇨🇦Montreal, Quebec, Canada
Burke Pharmaceutical Research
🇺🇸Hot Springs, Arkansas, United States
Park Avenue Dermatology, PA
🇺🇸Orange Park, Florida, United States
Innovaderm Research Inc
🇨🇦Montreal, Quebec, Canada
Zdrowie Osteo-Medic s.c. Lidia i Artur Racewicz, Agnieszka i Jerzy Supronik
🇵🇱Bialystok, Poland
Gabinet Lekarski RTG USG Dr n. med. Pawel Skrzywanek; Pracownia Radiologiczna
🇵🇱Poznan, Poland
Wojskowy Instytut Medyczny
🇵🇱Warszawa 44, Poland
Michigan Center for Skin Care Research
🇺🇸Clinton Township, Michigan, United States
Ultranova Skincare
🇨🇦Barrie, Ontario, Canada
Klinika Ambroziak ESTEDERM Sp. z o.o.SKA
🇵🇱Warszawa, Mazowieckie, Poland
Krakowskie Centrum Medyczne Sp. z o.o.
🇵🇱Krakow, Poland
High-Med. Przychodnia Specjalistyczna
🇵🇱Warszawa, Poland
NZOZ multiMedica
🇵🇱Wroclaw, Poland
SKiN Centre for Dermatology
🇨🇦Peterborough, Ontario, Canada
Dermatology Research Associates
🇺🇸Nashville, Tennessee, United States
Lee Medical Associates
🇺🇸San Antonio, Texas, United States
Olympian Clinical Research
🇺🇸Tampa, Florida, United States
Massachusetts General Hospital - Clinical Unit for Research Trials in Skin (CURTIS)
🇺🇸Boston, Massachusetts, United States
Oregon Dermatology and Research Center
🇺🇸Portland, Oregon, United States
Oregon Medical Research Center, PC
🇺🇸Portland, Oregon, United States
Menter Dermatology Research Institute
🇺🇸Dallas, Texas, United States
Lynderm Research Inc
🇨🇦Markham, Ontario, Canada
UC Irvine Dermatology Research
🇺🇸Irvine, California, United States
Bakersfield Dermatology and Skin Cancer Medical Center
🇺🇸Bakersfield, California, United States
Atlanta Dermatology, Vein & Research Center
🇺🇸Alpharetta, Georgia, United States
Advanced Medical Research, Inc
🇺🇸Atlanta, Georgia, United States
Dundee Dermatology
🇺🇸West Dundee, Illinois, United States
Tufts Medical Center
🇺🇸Boston, Massachusetts, United States
Dermatology Consulting Services
🇺🇸High Point, North Carolina, United States
Clinical Partners, LLC
🇺🇸Johnston, Rhode Island, United States
Arlington Research Center Inc.
🇺🇸Arlington, Texas, United States
Dermatology Treatment and Research Center
🇺🇸Dallas, Texas, United States
Suzanne Bruce and Associates, PA
🇺🇸Houston, Texas, United States
Progressive Clinical Research
🇺🇸San Antonio, Texas, United States
K. Papp Clinical Research Inc.
🇨🇦Waterloo, Ontario, Canada
Dermatologisk Afdeling S
🇩🇰Aarhus C, Denmark
Hudklinikken Herning
🇩🇰Herning, Denmark
NZOZ Centrum Osteoporozy i Chorob Kostno-Stawowych J. Badurski Spolka Jawna
🇵🇱Bialystok, Poland
Maxxmed Centrum Zdrowia i Urody
🇵🇱Lublin, Poland
Wake Forest University Health Sciences
🇺🇸Winston-Salem, North Carolina, United States
XLR8 Medical Research
🇨🇦Windsor, Ontario, Canada
Rhode Island Hospital
🇺🇸Providence, Rhode Island, United States